SLC5A2 and diabetes mellitus: Included individuals were primarily female (62.9%) and had a median age of 49 years (IQR 42–55 years), they had a higher CCI score (moderate low [16.3 vs. 12.8%] and moderate high [8.9 vs. 5.5%], p < 0.01), shorter duration of diabetes (5.1 vs. 6.2 years, p < 0.01), better glycemic stability (HbA1c 6.5% vs. 7.0% [48.0 vs. 53.0 mmol/l], p < 0.01) as well as more frequent use of metformin (82.1 vs. 70.3%, < 0.01), antihypertensive medications (73.4 vs. 56.6%, < 0.01), GLP-1 analogues (49.5 vs. 21.1%, p < 0.01) and SGLT-2 inhibitors (17.7 vs. 14.4%, p = 0.04) than controls at index date.